ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements
Molbio Diagnostics Limited re-appointed M/s. K.S. Kamalakara & Co as Cost Auditors for a 12-month term. The decision was finalized during a board meeting on September 25, 2026.
Molbio Diagnostics Limited has re-appointed M/s K. S. Kamalakara & Co as its Cost Auditor for the financial year 2026-27. The Board approved the appointment today.
India Business Excellence Fund III sold 30,00,000 shares (2.60% stake) of Molbio Diagnostics Limited. The transaction was executed via open market on September 23, 2026.
Molbio reported Q1 FY27 revenue of ₹408 Cr with a 25% EBITDA margin. Strategy focuses on expanding Truenat's global footprint and integrating digital pathology via OptraScan.
Molbio Diagnostics informed exchanges that its CIN changed from U33125GA2000PLC002909 to L33125GA2000PLC002909 post-listing. The MCA status was updated from Unlisted to Listed.
Molbio Diagnostics listed on Aug 17, 2026. Q1 FY27 saw Total Income of ₹411.5 Cr and EBITDA of ₹103.7 Cr, transitioning from a loss in Q1 FY26 driven by higher test-kit consumption.
Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 Cr and PAT of ₹52.74 Cr, a swing from prior-year losses. Growth was driven by Truenat test-kit volume and deferred Gulf export orders.
Molbio Diagnostics Ltd reported revenue from operations of ₹408.4 Cr (+309.6% YoY) and net profit of ₹52.7 Cr for Q1 FY27.